Symptoms and diagnosis
Usage examples
Medicinal plants
Frequent searches
Medical search
Health topics
Healthy weight
Medical dictionary
Health sites
Questions and answers
Oncothyreon (ONTY) Price Target Lowered to $3 at Wedbush
"While we are removing tecemotide from our valuation, we are adding the opportunity for ONTY's newly acquired protocell technology in primary hyperoxaluria type 1 (PH-1). Protocell technology, gained as part of the recent Alpine Biosciences acquisition ... (subscription) - Tue, 19 Aug 2014 05:33

Dicerna Provides Operational Update and Reports Second Quarter 2014 ...
DCR-PH1 is a therapeutic candidate for Primary Hyperoxaluria 1 (PH1), a rare, inherited autosomal recessive disorder of metabolism in the liver that usually results in life-threatening damage to the kidneys. In the genetic mouse model of PH1, Dicerna ...
Business Wire (press release) - Thu, 07 Aug 2014 12:52

Dicerna On Track with Drug Candidates, Initial Cancer Rx Data Expected in '15
NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this month confirmed previous guidance on its two drug candidates, the solid tumor therapy DCR-MYC and the primary hyperoxaluria 1 (PH1) treatment DCR-PH1, stating that both agents remain on track ...
GenomeWeb - Thu, 21 Aug 2014 07:30


Last update: September 2014

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014